Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma

被引：181
|
作者：
Braun, David A. [1 ]
Ishii, Yuko [2 ]
Walsh, Alice M. [2 ]
Van Allen, Eliezer M. [1 ]
Wu, Catherine J. [1 ]
Shukla, Sachet A. [1 ]
Choueiri, Toni K. [1 ]
机构：
[1] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA
[2] Bristol Myers Squibb, Lawrenceville, NJ USA
来源：
JAMA ONCOLOGY | 2019年 / 5卷 / 11期
关键词：
D O I：
10.1001/jamaoncol.2019.3158
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1631 / 1633
页数：3
相关论文
共 50 条
  • [1] The Impact of PBRM1 Expression as a Prognostic and Predictive Marker in Metastatic Renal Cell Carcinoma
    Kim, Ji-Yeon
    Lee, Se-Hoon
    Moon, Kyung Chul
    Kwak, Cheol
    Kim, Hyeon Hoe
    Keam, Bhumsuk
    Kim, Tae Min
    Heo, Dae Seog
    JOURNAL OF UROLOGY, 2015, 194 (04): : 1112 - 1119
  • [2] PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma
    Xian-De Liu
    Wen Kong
    Christine B. Peterson
    Daniel J. McGrail
    Anh Hoang
    Xuesong Zhang
    Truong Lam
    Patrick G. Pilie
    Haifeng Zhu
    Kathryn E. Beckermann
    Scott M. Haake
    Sevinj Isgandrova
    Margarita Martinez-Moczygemba
    Nidhi Sahni
    Nizar M. Tannir
    Shiaw-Yih Lin
    W. Kimryn Rathmell
    Eric Jonasch
    Nature Communications, 11
  • [3] PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma
    Liu, Xian-De
    Kong, Wen
    Peterson, Christine B.
    McGrail, Daniel J.
    Anh Hoang
    Zhang, Xuesong
    Truong Lam
    Pilie, Patrick G.
    Zhu, Haifeng
    Beckermann, Kathryn E.
    Haake, Scott M.
    Isgandrova, Sevinj
    Martinez-Moczygemba, Margarita
    Sahni, Nidhi
    Tannir, Nizar M.
    Lin, Shiaw-Yih
    Rathmell, W. Kimryn
    Jonasch, Eric
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [4] PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in NSCLC
    Liu, J.
    Zhou, H.
    Zhang, Y.
    Huang, Y.
    Yang, Y.
    Fang, W.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [5] Prognostic role of PBRM1 marker expression in clear-cell renal-cell carcinoma
    Zaridze, D. G.
    Mazurenko, N. N.
    Bezhanova, S. D.
    Maksimovich, D. M.
    Shangina, O., V
    Draudin-Krylenko, V. A.
    Mukeria, A. F.
    Matveev, V. B.
    ONKOUROLOGIYA, 2019, 15 (01): : 23 - 31
  • [6] A germline mutation in PBRM1 predisposes to renal cell carcinoma
    Benusiglio, Patrick R.
    Couve, Sophie
    Gilbert-Dussardier, Brigitte
    Deveaux, Sophie
    Le Jeune, Helene
    Da Costa, Melanie
    Fromont, Gaelle
    Memeteau, Francoise
    Yacoub, Mokrane
    Coupier, Isabelle
    Leroux, Dominique
    Mejean, Arnaud
    Escudier, Bernard
    Giraud, Sophie
    Gimenez-Roqueplo, Anne-Paule
    Blondel, Christophe
    Frouin, Eric
    Teh, Bin T.
    Ferlicot, Sophie
    Bressac-de Paillerets, Brigitte
    Richard, Stephane
    Gad, Sophie
    JOURNAL OF MEDICAL GENETICS, 2015, 52 (06) : 426 - 430
  • [7] PBRM1 and BAP1 expression in renal cell carcinoma
    Kuthi, L.
    Fallmann, E.
    Jenei, A.
    Posfai, B.
    Maraz, A.
    VIRCHOWS ARCHIV, 2018, 473 : S44 - S44
  • [8] Loss of PBRM1 expression is associated with renal cell carcinoma progression
    Pawlowski, Rafal
    Muehl, Sarah M.
    Sulser, Tullio
    Krek, Wilhelm
    Moch, Holger
    Schraml, Peter
    INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (02) : E11 - E17
  • [9] Immune microenvironment in clear cell type renal cell carcinoma with loss of PBRM1 protein expression
    Miura, Yuji
    Motoshima, Takanobu
    Inoshita, Naoko
    Okaneya, Toshikazu
    Takano, Toshimi
    Komohara, Yoshihiro
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] Prognostic and clinicopathological value of PBRM1 expression in renal cell carcinoma
    Wang, Zhun
    Peng, Shuanghe
    Guo, Linpei
    Xie, Hui
    Wang, Aixiang
    Shang, Zhiqun
    Niu, Yuanjien
    CLINICA CHIMICA ACTA, 2018, 486 : 9 - 17
12345